Ralaniten acetate

From WikiMD.org
Jump to navigation Jump to search

Ralaniten Acetate

Ralaniten Acetate (pronunciation: rah-lan-ih-ten a-seh-tate) is a non-steroidal antiandrogen that is used in the treatment of prostate cancer. It is also known by its developmental code name EPI-506.

Etymology

The name "Ralaniten" is derived from the chemical structure of the compound, which includes a ralanite moiety. The "acetate" part of the name refers to the presence of an acetate group in the chemical structure.

Pharmacology

Ralaniten acetate works by binding to the androgen receptor, thereby preventing androgens (male hormones) from binding to the receptor and stimulating the growth of prostate cancer cells. It is a derivative of ralaniten, a compound that was originally developed as a treatment for benign prostatic hyperplasia (BPH).

Clinical Use

Ralaniten acetate is currently being investigated in clinical trials for the treatment of prostate cancer. It is specifically being studied for use in patients with castration-resistant prostate cancer (CRPC), a form of the disease that is resistant to traditional hormone therapy.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski